Teva launches generic version of Epzicom tablets in U.S.

Teva Pharmaceutical Industries has launched Abacavir and Iamivudine tablets, the company’s generic version of Epzicom tablets, in the United States.

The dosages for the Abacavir and Iamivudine tablets, which are designed to treat HIV-1 infections in combination with other antiretroviral agents, will be 600 mg and 300 mg.

According to Teva, when Abacavir and Iamivudine are combined with antiretroviral agents, the resulting tablets can reduce the amount of HIV-1 in affected patients’ blood (viral load), and increase the number of CD4+ (T) cells in affected patients’ blood to help fight off other infections.

The new tablets were developed to reduce the amount of HIV-1 and increase CD4+ (T) cells in the blood. Doing so would help improve the immune systems of patients and could potentially decrease the risk of death or infections, which are the result of a weakened immune system. Teva has maintained that its new medication is not a cure for HIV or AIDS.

Abacavir and Iamivudine tablets are part of Teva’s dedication to strengthen its generics portfolio by devoting time to the development of newer, generic products of a higher quality. Teva has the largest generic products line with approximately 600 FDA-approved medications.